EQRx Confronts US Drug Development Realities, Shifts Pricing Approach
Company’s $1.5bn To Last Into 2028
Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.
